10
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Rational Perspectives on Risk and Certainty for Dentistry During the COVID-19 Pandemic

      discussion

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The risk of infection in dentistry The practice of dentistry exposes dental health professionals and patients to infectious disease agents. 1 The risk is considered to be higher in dental practices than in other health care settings, mainly because there is close and prolonged contact between provider and patient. In addition, most dental procedures generate aerosols that are contaminated with a patient's saliva, blood, other secreta, or tissue particles. 2 To control this risk, the U.S. Centers for Disease Control and Prevention (CDC) and other organizations developed recommendations and protocols based on the principle of standard precautions. 3 , 4 The fundamental elements in these recommendations are the use of physical barriers between patient and provider, instrument sterilization, and environmental reprocessing. SARS-CoV-2, the virus causing COVID-19, is transmitted primarily through respiratory droplets and aerosols when an infected person coughs, sneezes, or talks. 5 , 6 In addition, there is evidence that pre-symptomatic or asymptomatic persons can transmit the virus. COVID-19 is of particular concern for dental settings because of aerosol-creating dental procedures. 5 , 6 To address this, the CDC developed “Interim infection prevention and control guidance for dental settings during COVID-19”. 7 The CDC's guidance states that the unique characteristics of the dental setting warrant special infection control considerations. In line with this, the Occupational Safety and Health Administration (OSHA) developed a COVID-19 workplace guidance document and an additional update entitled “Dentistry Workers and Employers”. 8 9 OSHA places dental health care providers in the “very high exposure risk” category in their recommendations for preparing workplaces for COVID-19, along with doctors, nurses, paramedics, and emergency medical technicians who perform aerosol-generating procedures on known or suspected COVID-19 patients. The CDC and OSHA, therefore, both stipulate that dental practices require enhanced precautions to protect the clinical team and patients from aerosols generated during clinical care. In addition, the CDC confirmed that care for dental emergencies should be provided at all times during a pandemic, but take into account the specific local risk scenarios. 10 The current status of COVID-19 among dental health care providers The CDC summarizes data from state health departments on SARS-CoV-2 infection including health care workers using a standardized case form. The CDC form does not differentiate between types of health care workers; specific information on COVID-19 among dental health care personnel is therefore not available. The CDC published a summary report on the characteristics of U.S. health care personnel diagnosed with COVID-19 in the United States through April 9, 2020. 11 While only 16 percent of all reported total infections contained data on whether the reported individual was a health care professional (HCP), 19 percent of HCP were reported as positive. From this group, 55 percent mentioned contact with a COVID-19 patient only in the health care setting, and the remainder in other settings. Among those infected, 2%-5% were admitted to ICU, and 0.3%-0.8% died. The CDC report warns that these numbers underestimate both, the infection and mortality rates, due to missing data and lack of information on the nature of interaction with suspected and/or confirmed COVID-19 patients. It is essential to understand that the lack of reported COVID-19 infections among dental health care personnel should not be taken as evidence for low or negligible risk for those working in dental settings. Rather, the CDC report supports the guidance documents that dental personnel are at high infection risk in a droplet or aerosol-generating environment. Dental services during the U.S response to COVID-19 In response to the rapidly evolving information and evidence, public health and professional organizations have taken the task of regularly reviewing and updating relevant information for dental services. To reduce infection spread during the COVID-19 pandemic, the CDC recommended that dental care providers delay elective ambulatory care visits, aligned with the recommendations for medical services. 7 The American Dental Association (ADA), similar to other professional national and global organizations, developed guidance taking into account the CDC and OSHA recommendations. 12 In addition, the ADA also published clear definitions of dental emergencies to guide dentists in their decisions. 13 The majority of U.S. dental practices complied with the CDC, OSHA, and ADA advice by offering only emergency services or closing completely. 14 As states are beginning to lift restrictions on small businesses and dental practices, they are leaving the decision to re-open clinics to the individual practice owners and making it challenging to follow the multitude of rapidly evolving guidance. Updated information on state-by-state recommendations for dental services, prepared by the National Network for Oral Health Access (NNOHA) is available at website of the Association of State and Territorial Dental Directors (ASTDD). 15 Even with re-opening recommendations of professional organizations, including bodies like the Organization for Safety and Asepsis Procedures in Dentistry (OSAP, www.osap.org), the question for dental teams remains whether it is safe to provide care in dental practices, and what changes will be required to balance the need for care and the risks of doing so. 12 , 16 What we know about COVID-19 infection risk in dental settings Central to ongoing discussions around the re-opening of dental services is the evaluation of infection risk. In the absence of more detailed information, assessments of COVID-19 infection risk are done by extrapolation. Extrapolation is common in clinical and public health practice when knowledge and emergency context are rapidly evolving. 17 Such rapid recommendations or guidelines are often labeled as “interim.” That said, there are a number of facts that can provide a sound basis from which principles for clinical care during the COVID-19 pandemic can be derived: All patients should be considered potentially infectious Transmission of SARS-Cov-2 can occur in pre-symptomatic or asymptomatic patients. In these encounters, medical history or body temperature offer no assurance of identifying infected individuals. Reliable and valid testing prior to dental care is not an option at this point in time because false-negative results cannot be ruled out. Also, vaccinations are not available, and the status of immunity after an infection is unclear. The only realistic and safe approach is to apply the principle of standard precautions. This means that, for now, all patients must be considered potentially infectious for airborne disease transmission and should be treated with equal and uniform precaution measures. Droplets and aerosols are the primary sources of infection COVID-19 is, therefore, an airborne infection because the primary sources of infection for SARS-CoV-2 are droplets and aerosols containing the virus. The practice of dentistry produces aerosols and droplets, involves direct contact with potentially infected mucosa, and comprises procedures that may induce gagging or coughing of patients, all carried out in close proximity to the patient's mouth and nose. 18 Dental practice exposes dental health personnel to these potentially infectious droplets and aerosols. Eliminating aerosol-generating procedures is the best protection. However, if care is acutely required and droplets are unavoidable, donning a comprehensive set of personal protective equipment (PPE) will reduce the risk of transmission. Such PPE is also used by respiratory therapists to intubate COVID-19 patients in health care settings. Other unique procedures for dentistry such as rubber dam, high-power suction, and physical barriers between patients and providers, may further reduce, but not eliminate the risk. Some novel aerosol scavenging systems (bioaerosol control devices) have been registered with the FDA, but there is no information on their efficacy in preventing airborne infections, especially in a dental setting. Airborne infections may require higher infection control measures than standard precautions The 2003 CDC recommendations for infection control focused on bloodborne pathogens, including hepatitis and HIV, and were later updated to address risk reduction of airborne pathogens like tuberculosis. 3 , 19 The latter guideline requires airborne infection isolation rooms (AIIR) using negative pressure ventilation to reduce airborne transmission risk. However, dental operatories are generally not designed as AIIR. Current clinical evidence indicates that for aerosol-generating procedures, enhanced PPE alone (handwashing, gloves, goggles, face shields, N95 face masks, and protective gowns), without AIIR, may reduce risk of transmission by approximately 90%. 20 Thus, a risk of transmission persists without AIIR, and infection with airborne pathogens cannot be ruled out. The current absence of evidence cannot be taken as evidence of absence. Personal Protective Equipment (PPE) required for dental care should be as safe as possible The CDC interim guidance for aerosol-generating dental procedures recommends the use of the highest level of PPE when treating COVID-19 patients. 7 With the remaining uncertainties about transmission risk beyond the evidence above, it is an ethical imperative to assume that all dental patients should be considered as potentially infectious. In acting with the principle of not doing any harm, maximum protective measures should be taken. Combined with the design limitations of dental operatories to appropriately and safely handle the risk of SARS-Cov-2 transmission, any consideration about providing dental care other than interventions that do not generate aerosols must be made with utmost caution. Reconciling risks and uncertainties with safety and increasing service challenges Based on our current knowledge, the COVID-19 pandemic will change the way dental services are provided. Aerosols need to be controlled, while PPE measures and patient triage procedures need to be enhanced. The possible availability of a vaccine in the mid-term provides only limited assurance because it will take time to reach effective vaccination rates and resurgence of COVID-19 or other viral outbreaks are expected. 21 Every practicing clinician, patients, staff, families, communities, and professional dental associations are at a crucial point of the pandemic. Dental health personnel are obliged to follow the ethical principle of providing the best possible dental care, including the elimination of potential risks and harms. At the same time, as owners of private practices or as health care companies providing dental services, they are facing existential impacts from reduced patient visits and loss of income resulting from service limitations or practice closures. Reconciling the conflict of risking their life or their livelihood in the context of the COVID-19 pandemic is not a welcome or easy choice. Decisions in this context must be based on scientific evidence or sound guidance when the evidence is still evolving. Solutions and compromises need to be revisited as the pandemic, and economic conditions change. 17 A pandemic is a highly dynamic process with differing scenarios within a country or state. Containment measures may entail that strict service limitations are required in one location or circumstance, but not in another, or that conditions for re-opening of services vary depending on the pandemic evolution over time. For some settings, just the availability of PPE may be a major constraining factor. Whatever the scenario, it will have domino effects with serious impacts on all oral health stakeholders. These changes will include dental supplies and manufacturers, the insurance industry, dental education, and research. Thus, there is an immediate and existential need for dentistry to develop rapid response protocols that limit the impact of this pandemic through the continued provision of safe dental care that minimizes risk and avoids procedures with aerosols. The concept of SAFE Dentistry (Safe Aerosol-free Emergent Dentistry) may be a step in this direction. 22 The pandemic has also unmasked inequities that characterize access to dental care and financial coverage in the U.S. From this perspective, a better, more equitable system that ensures everyone's health and safety is needed. The profession needs to strive towards a future of oral health care that addresses population oral health needs, includes reliable surveillance to assess risk and outcomes, as well as improves preparedness and risk protection, while defining the best policy options for the current and future pandemics.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Transmission routes of 2019-nCoV and controls in dental practice

          A novel β-coronavirus (2019-nCoV) caused severe and even fetal pneumonia explored in a seafood market of Wuhan city, Hubei province, China, and rapidly spread to other provinces of China and other countries. The 2019-nCoV was different from SARS-CoV, but shared the same host receptor the human angiotensin-converting enzyme 2 (ACE2). The natural host of 2019-nCoV may be the bat Rhinolophus affinis as 2019-nCoV showed 96.2% of whole-genome identity to BatCoV RaTG13. The person-to-person transmission routes of 2019-nCoV included direct transmission, such as cough, sneeze, droplet inhalation transmission, and contact transmission, such as the contact with oral, nasal, and eye mucous membranes. 2019-nCoV can also be transmitted through the saliva, and the fetal–oral routes may also be a potential person-to-person transmission route. The participants in dental practice expose to tremendous risk of 2019-nCoV infection due to the face-to-face communication and the exposure to saliva, blood, and other body fluids, and the handling of sharp instruments. Dental professionals play great roles in preventing the transmission of 2019-nCoV. Here we recommend the infection control measures during dental practice to block the person-to-person transmission routes in dental clinics and hospitals.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine

            The epidemic of coronavirus disease 2019 (COVID-19), originating in Wuhan, China, has become a major public health challenge for not only China but also countries around the world. The World Health Organization announced that the outbreaks of the novel coronavirus have constituted a public health emergency of international concern. As of February 26, 2020, COVID-19 has been recognized in 34 countries, with a total of 80,239 laboratory-confirmed cases and 2,700 deaths. Infection control measures are necessary to prevent the virus from further spreading and to help control the epidemic situation. Due to the characteristics of dental settings, the risk of cross infection can be high between patients and dental practitioners. For dental practices and hospitals in areas that are (potentially) affected with COVID-19, strict and effective infection control protocols are urgently needed. This article, based on our experience and relevant guidelines and research, introduces essential knowledge about COVID-19 and nosocomial infection in dental settings and provides recommended management protocols for dental practitioners and students in (potentially) affected areas.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Characteristics of Health Care Personnel with COVID-19 — United States, February 12–April 9, 2020

              As of April 9, 2020, the coronavirus disease 2019 (COVID-19) pandemic had resulted in 1,521,252 cases and 92,798 deaths worldwide, including 459,165 cases and 16,570 deaths in the United States ( 1 , 2 ). Health care personnel (HCP) are essential workers defined as paid and unpaid persons serving in health care settings who have the potential for direct or indirect exposure to patients or infectious materials ( 3 ). During February 12–April 9, among 315,531 COVID-19 cases reported to CDC using a standardized form, 49,370 (16%) included data on whether the patient was a health care worker in the United States; including 9,282 (19%) who were identified as HCP. Among HCP patients with data available, the median age was 42 years (interquartile range [IQR] = 32–54 years), 6,603 (73%) were female, and 1,779 (38%) reported at least one underlying health condition. Among HCP patients with data on health care, household, and community exposures, 780 (55%) reported contact with a COVID-19 patient only in health care settings. Although 4,336 (92%) HCP patients reported having at least one symptom among fever, cough, or shortness of breath, the remaining 8% did not report any of these symptoms. Most HCP with COVID-19 (6,760, 90%) were not hospitalized; however, severe outcomes, including 27 deaths, occurred across all age groups; deaths most frequently occurred in HCP aged ≥65 years. These preliminary findings highlight that whether HCP acquire infection at work or in the community, it is necessary to protect the health and safety of this essential national workforce. Data from laboratory-confirmed COVID-19 cases voluntarily reported to CDC from 50 states, four U.S. territories and affiliated islands, and the District of Columbia, during February 12–April 9 were analyzed. Cases among persons repatriated to the United States from Wuhan, China, and the Diamond Princess cruise ship during January and February were excluded. Public health departments report COVID-19 cases to CDC using a standardized case report form* that collects information on patient demographics, whether the patient is a U.S. health care worker, symptom onset date, specimen collection dates, history of exposures in the 14 days preceding illness onset, COVID-19 symptomology, preexisting medical conditions, and patient outcomes, including hospitalization, intensive care unit (ICU) admission, and death. HCP patient health outcomes, overall and stratified by age, were classified as hospitalized, hospitalized with ICU admission, and deaths. The lower bound of these percentages was estimated by including all cases within each age group in the denominators. Upper bounds were estimated by including only those cases with known information on each outcome as denominators. Data reported to CDC are preliminary and can be updated by health departments over time. The upper quartile of the lag between onset date and reporting to CDC was 10 days. Because submitted forms might have missing or unknown information at the time of report, all analyses are descriptive, and no statistical comparisons were performed. Stata (version 15.1; StataCorp) and SAS (version 9.4; SAS Institute) were used to conduct all analyses. Among 315,531 U.S. COVID-19 cases reported to CDC during February 12–April 9, data on HCP occupational status were available for 49,370 (16%), among whom 9,282 (19%) were identified as HCP (Figure). Data completeness for HCP status varied by reporting jurisdiction; among 12 states that included HCP status on >80% of all reported cases and reported at least one HCP patient, HCP accounted for 11% (1,689 of 15,194) of all reported cases. FIGURE Daily number of COVID-19 cases, by date of symptom onset, among health care personnel and non-health care personnel (N = 43,986)* , † — United States, February 12–April 9, 2020 Abbreviation: COVID-19 = coronavirus disease 2019. * Onset date was calculated for 5,892 (13%) cases where onset date was missing. This was done by subtracting 4 days (median interval from symptom onset to specimen collection date) from the date of earliest specimen collection. Cases with unknown onset and specimen collection dates were excluded. † Ten-day window is used to reflect the upper quartile in lag between the date of symptom onset and date reported to CDC. The figure is a bar chart showing the number of reported COVID-19 cases among health care personnel and non-health care personnel (N = 43,986), by date of illness onset, in the United States during February 12–April 9, 2020. Among the 8,945 (96%) HCP patients reporting age, the median was 42 years (IQR = 32–54 years); 6,603 (73%) were female (Table 1). Among the 3,801 (41%) HCP patients with available data on race, a total of 2,743 (72%) were white, 801 (21%) were black, 199 (5%) were Asian, and 58 (2%) were other or multiple races. Among 3,624 (39%) with ethnicity specified, 3,252 (90%) were reported as non-Hispanic/Latino and 372 (10%) as Hispanic/Latino. At least one underlying health condition † was reported by 1,779 (38%) HCP patients with available information. TABLE 1 Demographic characteristics, exposures, symptoms, and underlying health conditions among health care personnel with COVID-19 (N = 9,282) — United States, February 12–April 9, 2020 Characteristic (no. with available information) No. (%) Age group (yrs) (8,945) 16–44 4,898 (55) 45–54 1,919 (21) 55–64 1,620 (18) ≥65 508 (6) Sex (9,067) Female 6,603 (73) Male 2,464 (27) Race (3,801) Asian 199 (5) Black 801 (21) White 2,743 (72) Other* 58 (2) Ethnicity (3,624) Hispanic/Latino 372 (10) Non-Hispanic/Latino 3,252 (90) Exposures†,§ (1,423) Only health care exposure 780 (55) Only household exposure 384 (27) Only community exposure 187(13) Multiple exposure settings¶ 72 (5) Symptoms reported§,** (4,707) Fever, cough, or shortness of breath†† 4,336 (92) Cough 3,694 (78) Fever§§ 3,196 (68) Muscle aches 3,122 (66) Headache 3,048 (65) Shortness of breath 1,930 (41) Sore throat 1,790 (38) Diarrhea 1,507 (32) Nausea or vomiting 923 (20) Loss of smell or taste¶¶ 750 (16) Abdominal pain 612 (13) Runny nose 583 (12) Any underlying health condition§,*** (4,733) 1,779 (38) Abbreviation: COVID-19 = coronavirus disease 2019. * “Other” includes patients who were identified as American Indian or Alaska Native (16), Native Hawaiian or Other Pacific Islander (22), or two or more races (20). † Cases were included in the denominator if the patient reported a known contact with a laboratory-confirmed COVID-19 patient within the 14 days before illness onset in a health care, household, or community setting. § Responses include data from standardized fields supplemented with data from free-text fields. ¶ Includes all patients with contact reported in more than one of these settings: health care, household, and community. ** Cases were included in the denominator if the patient had a known symptom status for fever, cough, shortness of breath, nausea or vomiting, and diarrhea. HCP with mild or asymptomatic infections might have been less likely to be tested, thus less likely to be reported. †† Includes all patients with at least one of these symptoms. §§ Patients were included if they had information for either measured or subjective fever variables and were considered to have a fever if “yes” was indicated for either variable. ¶¶ Symptom data on loss of smell or taste was extracted only from free-text symptom fields, thus the proportion with this symptom is likely an underestimate. *** Preexisting medical conditions and other risk factors (yes, no, or unknown) included the following: chronic lung disease (inclusive of asthma, chronic obstructive pulmonary disease, and emphysema); diabetes mellitus; cardiovascular disease; chronic renal disease; chronic liver disease; immunocompromised condition; neurologic disorder, neurodevelopmental or intellectual disability; pregnancy; current smoking status; former smoking status; or other chronic disease. Among 1,423 HCP patients who reported contact with a laboratory-confirmed COVID-19 patient in either health care, household, or community settings, 780 (55%) reported having such contact only in a health care setting within the 14 days before their illness onset; 384 (27%) reported contact only in a household setting; 187 (13%) reported contact only in a community setting; 72 (5%) reported contact in more than one of these settings. Among HCP patients with data available on a core set of signs and symptoms, § a total of 4,336 (92%) reported having at least one of fever, cough, shortness of breath. Two thirds (3,122, 66%) reported muscle aches, and 3,048 (65%) reported headache. Loss of smell or taste was written in for 750 (16%) HCP patients as an “other” symptom. Among HCP patients with data available on age and health outcomes, 6,760 (90%) were not hospitalized, 723 (8%–10%) were hospitalized, 184 (2%–5%) were admitted to an ICU, and 27 (0.3%–0.6%) died (Table 2). Although only 6% of HCP patients were aged ≥65 years, 10 (37%) deaths occurred among persons in this age group. TABLE 2 Hospitalizations,* intensive care unit (ICU) admissions, † and deaths, § by age group among health care personnel with COVID-19 — United States, February 12–April 9, 2020 Age group¶ (yrs) (no. of cases) Outcome, no. (%)** Hospitalization†† ICU admission Death 16–44 (4,898) 260 (5.3–6.4) 44 (0.9–2.2) 6 (0.1–0.3) 45–54 (1,919) 178 (9.3–11.1) 51 (2.7–6.3) 3 (0.2–0.3) 55–64 (1,620) 188 (11.6–13.8) 54 (3.3–7.5) 8 (0.5–1.0) ≥65 (508) 97 (19.1–22.3) 35 (6.9–16.0) 10 (2.0–4.2) Total (8,945) 723 (8.1–9.7) 184 (2.1–4.9) 27 (0.3–0.6) Abbreviation: COVID-19 = coronavirus disease 2019. * Hospitalization status known for 7,483 (84%) patients. † ICU status known for 3,739 (42%) patients. § Death outcomes known for 4,407 (49%) patients. ¶ Age status known for 8,945 (96%) patients. ** Lower bound of range = number of persons hospitalized, admitted to ICU, or who died among total in age group; upper bound of range = number of persons hospitalized, admitted to ICU, or who died among total in age group with known hospitalization status, ICU admission status, or death. †† Hospitalization status includes hospitalization with or without ICU admission. Discussion As of April 9, 2020, a total of 9,282 U.S. HCP with confirmed COVID-19 had been reported to CDC. This is likely an underestimation because HCP status was available for only 16% of reported cases nationwide. HCP with mild or asymptomatic infections might also have been less likely to be tested, thus less likely to be reported. Overall, only 3% (9,282 of 315,531) of reported cases were among HCP; however, among states with more complete reporting of HCP status, HCP accounted for 11% (1,689 of 15,194) of reported cases. The total number of COVID-19 cases among HCP is expected to rise as more U.S. communities experience widespread transmission. Compared with reports of COVID-19 patients in the overall populations of China and Italy ( 4 , 5 ), reports of HCP patients in the United States during February 12–April 9 were slightly younger, and a higher proportion were women; this likely reflects the age and sex distributions among the U.S. HCP workforce. Race and ethnicity distributions among HCP patients reported to CDC are different from those in the overall U.S. population but are more similar to those in the HCP workforce. ¶ , ** Among HCP patients who reported having contact with a laboratory-confirmed COVID-19 patient in health care, household, or community settings, the majority reported contact that occurred in health care settings. However, there were also known exposures in households and in the community, highlighting the potential for exposure in multiple settings, especially as community transmission increases. Further, transmission might come from unrecognized sources, including presymptomatic or asymptomatic persons ( 6 , 7 ). Together, these exposure possibilities underscore several important considerations for prevention. Done alone, contact tracing after recognized occupational exposures likely will fail to identify many HCP at risk for developing COVID-19. Additional measures that will likely reduce the risk for infected HCP transmitting the virus to colleagues and patients include screening all HCP for fever and respiratory symptoms at the beginning of their shifts, prioritizing HCP for testing, and ensuring options to discourage working while ill (e.g., flexible and nonpunitive medical leave policies). Given the evidence for presymptomatic and asymptomatic transmission ( 7 ), covering the nose and mouth (i.e., source control) is recommended in community settings where other social distancing measures are difficult to maintain. †† Assuring source control among all HCP, patients, and visitors in health care settings is another promising strategy for further reducing transmission. Even if everyone in a health care setting is covering their nose and mouth to contain their respiratory secretions, it is still critical that, when caring for patients, HCP continue to wear recommended personal protective equipment (PPE) (e.g., gown, N95 respirator [or facemask if N95 is not available], eye protection, and gloves for COVID-19 patient care). Training of HCP on preventive measures, including hand hygiene and PPE use, is another important safeguard against transmission in health care settings. Among HCP with COVID-19 whose age status was known, 8%–10% were reported to be hospitalized. This is lower than the 21%–31% of U.S. COVID-19 cases with known hospitalization status described in a recent report ( 8 ) and might reflect the younger median age (42 years) of HCP patients compared with that of reported COVID-19 patients overall, as well as prioritization of HCP for testing, which might identify less severe illness. Similar to earlier findings ( 8 ), increasing age was associated with a higher prevalence of severe outcomes, although severe outcomes, including death, were observed in all age groups. Preliminary estimates of the prevalence of underlying health conditions among all patients with COVID-19 reported to CDC through March 2020 ( 9 ) suggested that 38% had at least one underlying condition, the same percentage found in this HCP patient population. Older HCP or those with underlying health conditions ( 8 , 9 ) should consider consulting with their health care provider and employee health program to better understand and manage their risks regarding COVID-19. The increased prevalence of severe outcomes in older HCP should be considered when mobilizing retired HCP to increase surge capacity, especially in the face of limited PPE availability §§ ; one consideration is preferential assignment of retired HCP to lower-risk settings (e.g., telemedicine, administrative assignments, or clinics for non–COVID-19 patients). The findings in this report are subject to at least five limitations. First, approximately 84% of patients were missing data on HCP status. Thus, the number of cases in HCP reported here must be considered a lower bound because additional cases likely have gone unidentified or unreported. Second, among cases reported in HCP, the amount of missing data varied across demographic groups, exposures, symptoms, underlying conditions, and health outcomes; cases with available information might differ systematically from those without available information. Therefore, additional data are needed to confirm findings about the impact of potentially important factors (e.g., disparities in race and ethnicity or underlying health conditions among HCP). Third, additional time will be necessary for full ascertainment of outcomes, such as hospitalization status or death. Fourth, details of occupation and health care setting were not routinely collected through case-based surveillance and, therefore, were unavailable for this analysis. Finally, among HCP patients who reported contact with a confirmed COVID-19 patient in a health care setting, the nature of this contact, including whether it was with a patient, visitor, or other HCP, and the details of potential occupational exposures, including whether HCP were unprotected (i.e., without recommended PPE) or were present during high risk procedures (e.g., aerosol-generating procedures) are unknown ( 10 ). It is critical to make every effort to ensure the health and safety of this essential national workforce of approximately 18 million HCP, both at work and in the community. Surveillance is necessary for monitoring the impact of COVID-19-associated illness and better informing the implementation of infection prevention and control measures. Improving surveillance through routine reporting of occupation and industry not only benefits HCP, but all workers during the COVID-19 pandemic. Summary What is already known about this topic? Limited information is available about COVID-19 infections among U.S. health care personnel (HCP). What is added by this report? Of 9,282 U.S. COVID-19 cases reported among HCP, median age was 42 years, and 73% were female, reflecting these distributions among the HCP workforce. HCP patients reported contact with COVID-19 patients in health care, household, and community settings. Most HCP patients were not hospitalized; however, severe outcomes, including death, were reported among all age groups. What are the implications for public health practice? It is critical to ensure the health and safety of HCP, both at work and in the community. Improving surveillance through routine reporting of occupation and industry not only benefits HCP, but all workers during the COVID-19 pandemic.
                Bookmark

                Author and article information

                Contributors
                Journal
                Am J Infect Control
                Am J Infect Control
                American Journal of Infection Control
                Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc.
                0196-6553
                1527-3296
                12 June 2020
                12 June 2020
                Affiliations
                [1 ]Adjunct Professor, Department Epidemiology & Health Promotion, Associate Director Epidemiology & Surveillance, WHO Collaborating Center Quality Improvement & Evidence-based Dentistry, College of Dentistry, New York University, 433 First Avenue, New York 10010 NY, United States
                [2 ]Research Professor, Department Epidemiology & Health Promotion, Associate Director Global Health & Policy, WHO Collaborating Center Quality Improvement & Evidence-based Dentistry, College of Dentistry, New York University, 433 First Avenue, New York 10010 NY, United States
                [3 ]Senior Research Fellow, Global Health Center, Geneva Graduate Institute for Policy Studies, Chemin Eugène-Rigot 2A, 1211 Geneva, Switzerland
                [4 ]Professor & Chair, Department Epidemiology & Health Promotion, Director, WHO Collaborating Center Quality Improvement & Evidence-based Dentistry, College of Dentistry, New York University, 433 First Avenue, New York 10010 NY, United States
                Author notes
                [* ]Corresponding author habib.benzian@ 123456nyu.edu
                Article
                S0196-6553(20)30368-0
                10.1016/j.ajic.2020.06.007
                7290219
                32534866
                1e610435-f0fc-4c74-a908-d3c4d9d9b74e
                © 2020 Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                Categories
                Article

                Comments

                Comment on this article